<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02072759</url>
  </required_header>
  <id_info>
    <org_study_id>NL44572.068.13</org_study_id>
    <nct_id>NCT02072759</nct_id>
  </id_info>
  <brief_title>Acetylcarnitine and Metabolic Flexibility</brief_title>
  <official_title>Preservation of Metabolic Flexibility by Acetylcarnitine Formation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Foundation for the Study of Diabetes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin resistant subjects and type 2 diabetic patients are characterized by a decreased&#xD;
      metabolic flexibility: a reduced capability to switch from fat oxidation in the basal state&#xD;
      to carbohydrate oxidation in the insulin-stimulated state. This metabolic inflexibility is an&#xD;
      early hallmark in the development of diabetes. Recent evidence suggests that a low carnitine&#xD;
      availability may limit acetylcarnitine formation, thereby reducing metabolic flexibility. We&#xD;
      propose to test the hypothesis that metabolic inflexibility in pre-diabetic subjects and&#xD;
      diabetic patients is due to a reduced capacity to form acetylcarnitines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Insulin resistant subjects and type 2 diabetic patients are characterized by a&#xD;
      decreased metabolic flexibility: a reduced capability to switch from fat oxidation in the&#xD;
      basal state to carbohydrate oxidation in the insulin-stimulated state. This metabolic&#xD;
      inflexibility is an early hallmark in the development of diabetes. Recent evidence suggests&#xD;
      that low carnitine availability may limit acetylcarnitine formation, thereby reducing&#xD;
      metabolic flexibility.&#xD;
&#xD;
      Objectives: We will investigate whether subjects with impaired glucose tolerance (IGT) show a&#xD;
      diminished capacity to form acetylcarnitine in the face of high substrate availability.&#xD;
      Therefore, we will use a novel non-invasive 1H-Magnetic Resonance Spectroscopy (1H-MRS)&#xD;
      protocol to determine in vivo, and in time, the formation of acetylcarnitine in skeletal&#xD;
      muscle. Additionally, we will examine whether carnitine supplementation increases the&#xD;
      capacity to form acetylcarnitine and improves metabolic flexibility and insulin sensitivity&#xD;
      in IGT subjects.&#xD;
&#xD;
      Study design: 12 subjects with IGT will be included and will be subjected to either placebo-&#xD;
      or carnitine treatment (daily capsules with 2g of L-carnitine or placebo) in a randomized,&#xD;
      placebo-controlled, double blind crossover design. After both interventions, acetylcarnitine&#xD;
      formation after a mixed meal will be determined by 1H-MRS and meal-induced changes in fat and&#xD;
      glucose oxidation by indirect calorimetry. The maximal acetylcarnitine formation will be&#xD;
      measured after a cycling test via 1H-MRS. A hyperinsulinemic-euglycemic clamp will be&#xD;
      performed to determine insulin sensitivity. Biopsies will be taken to measure free carnitine&#xD;
      and carnitine acetyltransferase (CrAT) activity. To investigate whether differences in&#xD;
      acetylcarnitine formation may be involved in variations in glucose tolerance, twelve control&#xD;
      subjects, matched for BMI and age but glucose tolerant (based on oral glucose tolerance test,&#xD;
      according to WHO criteria) will also be included and will undergo all measurements once&#xD;
      without any intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>metabolic flexibility</measure>
    <time_frame>36 days</time_frame>
    <description>delta RER between basal and insulin-stimulated state)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>36 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>exercise-induced acetylcarnitine concentrations</measure>
    <time_frame>36 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>meal-induced acetylcarnitine formation</measure>
    <time_frame>36 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CrAT activity</measure>
    <time_frame>36 days</time_frame>
    <description>determined in muscle biopsy samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasted blood plasma levels of FFA, triglycerides and glucose and post-meal area under the curve (AUC)</measure>
    <time_frame>36 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Maximal aerobic capacity (VO2max)</measure>
    <time_frame>screening</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Body composition (DEXA)</measure>
    <time_frame>screening</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Glucose tolerance (OGTT)</measure>
    <time_frame>screening</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Glucose Intolerance</condition>
  <arm_group>
    <arm_group_label>Carnitine supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carnitine supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carnitine supplement</intervention_name>
    <description>Carnitine supplement (oral ingestion with meals)&#xD;
Total dosage of 2g carnitine per day for 36 days.&#xD;
1 carnitine supplement at breakfast (500mg)&#xD;
1 carnitine supplement at lunch (500mg)&#xD;
2 carnitine supplements at diner (2x 500mg=1000mg)</description>
    <arm_group_label>Carnitine supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 40-70 years&#xD;
&#xD;
          -  Overweight/obese, BMI 25-35 kg/m2&#xD;
&#xD;
          -  Stable dietary habits&#xD;
&#xD;
          -  Generally healthy with no medication use that interferes with metabolism&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fasting plasma glucose &gt;7.1 mmol/l&#xD;
&#xD;
          -  Haemoglobin &lt;7.8 mmol/l&#xD;
&#xD;
          -  Hypertension: blood pressure &gt; 140 mmHg systolic or 90 mmHg diastolic&#xD;
&#xD;
          -  Cardiac problems, such as angina pectoris, cardiac infarction and arrhythmias&#xD;
&#xD;
          -  Plasma creatinine concentration higher than 115 micromol/l (in men) en 100 micromol&#xD;
             (in women).&#xD;
&#xD;
          -  Any medical condition requiring treatment and/or medication that interferes with&#xD;
             investigated parameters&#xD;
&#xD;
          -  Unstable body weight (weight gain or loss &gt; 3 kg in the past three months)&#xD;
&#xD;
          -  Participation in another biomedical study within 1 month prior to the screening visit&#xD;
&#xD;
          -  Subjects with contra-indication for MRI&#xD;
&#xD;
          -  Subjects, who do not want to be informed about unexpected medical findings, or do not&#xD;
             wish that their treating physician is informed, cannot participate in the study.&#xD;
&#xD;
          -  Subject are not allowed to donate blood three months prior to the start of the study&#xD;
             and three months after finishing the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vera B Schrauwen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>February 25, 2014</study_first_submitted>
  <study_first_submitted_qc>February 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2014</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Metabolic flexibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

